0000000001169845

AUTHOR

Ennio Lubrano

showing 4 related works from this author

Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey

2022

Spondyloarthritis are chronic inflammatory diseases affecting spine, peripheral joints and enthesis, as well as extra-articular sites (bowel, eyes, skin). Diagnosis of spondyloarthritis often is slow and requires a multidisciplinary approach. The “Early SpA Clinic” project aimed at improving the patient care and journeys, by solving some organizational issues existing in Rheumatology Clinics. The “Early SpA Clinic” involved 19 Italian Rheumatology Centers using in-depth organizational analyses to identify areas for improvement. From the results of the analyses, some organizational solutions were suggested, and their impact measured at the end of the project through specific KPI. With the im…

hospital organizationSettore MED/16 - REUMATOLOGIAspondyloarthritis.Early SpA Clinicearly diagnosipatient journeyrheumatologyGeneral MedicineEarly SpA Clinic; early diagnosis; hospital management; hospital organization; patient journey; rheumatology; spondyloarthritis.hospital managementspondyloarthritisearly diagnosis
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

2018

Objectives To review the available evidence concerning the possibility of discontinuing and/or tapering the dosage of TNF inhibitors (TNFi) in RA patients experiencing clinical remission or low disease activity. Methods A systematic review of the literature concerning the low dosage and discontinuation of TNFi in disease-controlled RA patients was performed by evaluation of reports published in indexed international journals (Medline via PubMed, EMBASE), in the time frame from 8 April 2013 to 15 January 2016. Results We analysed the literature evaluating the efficacy and the safety of two different strategies using TNFi, decreasing dosage or discontinuation, in patients experiencing clinica…

Drugmedicine.medical_specialtymedia_common.quotation_subjectMEDLINEArthritisEtanerceptDose-Response RelationshipArthritis Rheumatoid03 medical and health sciences0302 clinical medicineRheumatologyRheumatoidInternal medicinemedicineAdalimumabHumansPharmacology (medical)030212 general & internal medicinemedia_common030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisRemission Inductionmedicine.diseaseRheumatologyAntirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Humans; Remission Induction; Tumor Necrosis Factor-alpha; Rheumatology; Pharmacology (medical)DiscontinuationRheumatoid arthritisAntirheumatic AgentsDrugbusinessmedicine.drugRheumatology (Oxford, England)
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct